必须声明标量变量 "@Script_ID"。 肠道菌群与炎症性肠病-《赣南医学院学报》

[1]谢 华,何良梅,刘 瑶,等.肠道菌群与炎症性肠病[J].赣南医学院学报,2017,37(04):659-663.[doi:10.3969/j.issn.1001-5779.2017.04.050]
 XIE Hua,HE Liang-mei,LIU Yao,et al.Gut Microbiota and Inflammatory Bowel Diseases[J].,2017,37(04):659-663.[doi:10.3969/j.issn.1001-5779.2017.04.050]
点击复制

肠道菌群与炎症性肠病()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
37
期数:
2017年04期
页码:
659-663
栏目:
出版日期:
2017-09-18

文章信息/Info

Title:
Gut Microbiota and Inflammatory Bowel Diseases
文章编号:
1001-5779(2017)04-0659-05
作者:
谢 华何良梅刘 瑶张自翔
赣南医学院第一临床医学院,江西 赣州 341000
Author(s):
XIE HuaHE Liang-meiLIU YaoZHANG Zi-xiang
The First Affliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000
关键词:
肠道菌群 炎症性肠病 益生菌 粪便移植
Keywords:
gut microbiota inflammatory bowel disease probiotics fecal microbiota transplantation
分类号:
R364.5
DOI:
10.3969/j.issn.1001-5779.2017.04.050
文献标志码:
A
摘要:
炎症性肠病(inflammatory bowel diseases,IBD)主要指溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD)。IBD的发病机制尚未明确,有研究认为各种环境因素作用于遗传易感者,在肠道菌群的参与下,启动肠道免疫系统及非免疫系统,最终诱发肠道产生炎症反应。与正常人相比,IBD患者的肠道存在不同程度的菌群失调,此文就肠道菌群在IBD发病中的作用及其治疗中的应用作一综述。
Abstract:
Inflammatory bowel diseases(IBD)mainly refers to the ulcerative colitis(UC)and Crohn's disease(CD). At present, the pathogenesis of IBD has not been clear, considering the effect of various environmental factors on genetic susceptibility. The presence of gut microbiota activate intestinal immune system and non immune system, inducing intestinal inflammatory reaction through a variety of mechanisms. Compared with the normal people, there are different degrees of gut microbiota imbalance in IBD patients. This article reviews the role of gut microbiota in the pathogenesis of IBD and its application in the treatment of the diseases.

参考文献/References:

[1] Molodecky N A,Soon I S,Rabi D M,et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012,142(1):46-54.
[2] 李玉清,洪莉.肠道菌群与儿科肠道炎症性疾病研究进展[J].临床儿科杂志,2016,34(1):59-63.
[3] Tremaroli V,Backhed F. Functional interactions between the gut microbiota and host metabolism[J]. Nature,2012,489(7415):242-249.
[4] 刘松珍,张雁,张名位,等. 肠道短链脂肪酸产生机制及生理功能的研究进展[J].广东农业科学,2013,40(11),99-103.
[5] 艾静,王承党. 丁酸盐与炎症性肠病的研究进展[J].胃肠病学,2014,19(1):47-49.
[6] Jan-Michael A,Klapproth,Maiko Sasaki.Bacterial Induction of Proinflammatory Cytokines in Inflammatory Bowel Disease[J].Inflamm Bowel Dis,2010,16(12):2173-2179.
[7] 张艳丽,刘新凤,于秀娟,等. 炎症性肠病患者肠道菌群变化及其与炎性因子的相关性[J].山东医药,2015,(10):79-80.
[8] Kabeerdoss J,Sankaran V,Puqazhendhi S,et al.Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India[J]. BMC Gastroenterol,2013:13-20.
[9] Cojocariu C,Stanciu C,Stoica O.Clostridium difficile infection and inflammatory bowel disease[J]. Turk J Gastroenterol,2014,25(6):603-610.
[10] Wright EK,Kamm MA,Teo SM,et al.Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn's Disease: A Systematic Review[J]. Inflamm Bowel Dis,2015,21(6):1219-1228.
[11] Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease[J].J Gastroenterol,2012,47(12):1298-1307.
[12] Walker AW,Sanderson JD,Churcher C,et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease[J].BMC Microbiol,2011,11:7.
[13] Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease[J].Adv Drug Deliv Rev,2007,59(11):1073-1083.
[14] Tremaroli V,Backhed F. Functional interactions between the gut microbiota and host metabolism[J]. Nature,2012,489(7415):242-249.
[15] Khan KJ, Ullman TA,Ford AC,et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and metaanalysis[J]. Am J Gastroenterol,2011,106(4):661-673.
[16] Ko Y,Butcher R,Leong RW,et al.Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases[J].World Journal of Gastroenterology,2015,20(5):1238-1247.
[17] Peloquin JM,Nguyen DD.The microbiota and inflammatory bowel disease:insights from animal models[J].Anaerobe,2013,24:102-106.
[18] Atarashi K,Tanoue T,Shima T,et al. Induction of colonic regulatory T cells by indigenous Clostridium species[J]. Science,2011,331(6015):337-341.
[19] Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota[J]. Science,2011,332(6032):974-977.
[20] Gevers D,Kugathasan S,Denson L,et al. The treatment naive microbiome in new-onset Crohn's disease[J]. Cell Host Microbe,2014,15(3):382-392.
[21] Cummings JH,Macfarlane GT,Macfarlane S. Intestinal bacteria and ulcerative co1itis[J].Curr Issues Intest Microbiol,2003,4(1):9-20.
[22] Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Inflamm Bowel Dis,2007,13(10):1277-1283.
[23] Obermeier F,Dunger N,Stauch UG,et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation[J]. Gastroterology,2005,129(3):913-927.
[24] 自爱平.炎症性肠病发病机制的微生物因素[J].世界华人消化杂志,2016,14(7):645-649.
[25] Furusawa Y,Obata Y,Fukuda S, et al. Commensal microbe-derived butyrate induces erentiation of colonic regulatory T cells[J]. Nature,2013,504(7480):446-450.
[26] Smith PM,Howitt MR,Panikov N,et al.The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis[J].Science,2013,341(6145):569-573.
[27] Maslowski KM, Vieira AT, Kranich J, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43[J].Nature,2009, 461(7268):1282-1286.
[28] Treem WR,Ahsan N,Shoup M,et al.Fecal short-chain fatty acids in children with inflammatory bowel disease[J].J Pediatr Gastroenterol Nutr,1994,18(2):159-164.
[29] Morgan XC,Tickle TL,Sokol H,et al.Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J].Genome Biol,2012,13(9):R79.
[30] Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J]. Gut,2011,60(4):463-472.
[31] Duboc H,Rajca S,Rainteau D,et al.Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases[J].Gut,2013,62(4):531-539.
[32] Devkota S,Wang Y,Musch MW,et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10-/- mice[J]. Nature,2012,487(7405):104-108.
[33] Dolan KT,Chang EB.Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases[J].Mol Nutr Res,2016:0-12.
[34] Monteleone I, Rizzo A, Sarra M, et al. Aryl hydrocarbon receptor induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract[J]. Gastroenterology,2011,141(1):237-248.
[35] Macpherson AJ,Slack E,Geuking MB,et al.The mucosal firewalls against commensal intestinal microbes[J].Seminars Immunopathology,2009,31(2):145-149.
[36] Kamada N,Chen GY,Inohara N,et al.Control of pathogens and pathobionts by the gut microbiota[J].Nature immunology,2013,14(7):685-690.
[37] Turovskiy Y, Sutyak Noll K, Chikindas ML. The aetiology of bacterial vaginosis[J]. J Appl Microbiology,2011,110(5):1105-1128.
[38] Hammami R, Fernandez B, Lacroix C,et al. Anti-infective properties of bacteriocins: an update[J].Cell Mol Life Sci,2013,70(16):297-2967.
[39] Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense[J]. Nature immunology,2012,13(5):449-456.
[40] Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine[J]. Science,2011,334(6053):255-258.
[41] Cario E. Bacterial interactions with cells of the intestinal mucosa:toll like receptors and NOD2[J]. Gut,2005,54(8):1182-1193.
[42] 周怡,刘红春.益生菌在炎症性肠病中的治疗进展[J].胃肠病学和肝病学杂志,2015(1):1-3.
[43] Miriam S,Jan W,Artur A,et al. Induction of human β-defensin 2 by the probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin[J].Infect Immun,2007,75(5): 2399-2407.
[44] Hegazy SK, El-Bedewy MM. Effect of probiotics on proinflammatory cytokines and NF-kappaB activation in ulcerative colitis[J].World J Gastroenterol,2010,16(33):4145-4151.
[45] 丁娟,熊光苏. 益生菌制剂VSL#3对溃疡性结肠炎诱导缓解作用的系统评价[J].胃肠病学,2012(9):521-526.
[46] Naidoo K, Gordon M, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis[J]. Cochrane Database Syst Rev,2011(12):D7443.
[47] Bourreille A,Cadiot G,Le Dreau G,et al.Saccharomyces boulardii does not prevent relapse of Crohn's disease[J]. Clin Gastroenterol Hepatol,2013,11(8):982-987.
[48] 王霄腾,戴金锋,吕宾. 益生茵对炎症性肠病诱导和维持缓解疗效的meta分析[J].胃肠病学,2015(1):29-35.
[49] Steed H, Macfarlane GT, Blackett KL,et al. Clinical trial: the microbiological and immunological effects of symbiotic consumption-a randomized double-blind placebo-controlled study in active Crohn's disease[J].Aliment Pharmacol Ther,2010(32):872-883.
[50] Chapman BC,Moore HB,Overbey DM,et al. Fecal microbiota transplant in patients with Clostridium difficile infection:A systematic review[J].Jrauma Acute Care Surq,2016,81(4):756-764.
[51] Tian Z, Liu J, Liao M, et al. Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice[J]. Dig Dis Sci,2016,61(8):2262-2271.
[52] Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J]. Aliment Pharmacol Ther,2014,39(10):1003-1032.
[53] Moayyedi P,Surette MG,Kim PT,et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial[J]. Gastroenterology,2015,149(1):102-109.
[54] Angelberger S,Reinisch W,Makristathis A,et al. Temporal Bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation[J].Am J Gastroenterol,2013,108(10):1620-1630.
[55] Suskind DL, Brittnacher MJ, Wahbeh G, et al. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease[J].Inflamm Bowel Dis,2015,21(3):556-563.

相似文献/References:

[1]谢 园,#,陈玲霞,等.肠道菌群在宿主抗柠檬酸杆菌感染中的作用和机制[J].赣南医学院学报,2019,39(10):973.[doi:10.3969/j.issn.1001-5779.2019.10.001]
 XIE Yuan,CHEN Ling-xia,LIU Yu-xia,et al.The role of gut microbiota in host resistance against Citrobacter rodentium infection[J].,2019,39(04):973.[doi:10.3969/j.issn.1001-5779.2019.10.001]
[2]古肖湘,吴雄健.粪便微生物移植研究现状及其在炎症性肠病中的应用[J].赣南医学院学报,2019,39(10):994.[doi:10.3969/j.issn.1001-5779.2019.10.005]
 GU Xiao-xiang,WU Xiong-jian.Current status of fecal microbial transplantation and its application in inflammatory bowel disease[J].,2019,39(04):994.[doi:10.3969/j.issn.1001-5779.2019.10.005]
[3]谢景春,谢保平,余丽梅.肠道菌群失衡对同种异体造血干细胞移植的影响[J].赣南医学院学报,2020,40(06):588.[doi:10.3969/j.issn.1001-5779.2020.06.012]
 XIE Jing-chun,XIE Bao-ping,YU Li-mei.Effects of intestinal microbiota imbalance on allogeneic hematopoietic stem cells transplantation[J].,2020,40(04):588.[doi:10.3969/j.issn.1001-5779.2020.06.012]

更新日期/Last Update: 2017-08-28